ABSTRACT
AIM: Frequency of detection determination for past and current hepatitis E virus (HEV) infection markers in children with immune suppression, as well as children with normal immune status. MATERIALS AND METHODS: The presence of HEV markers (anti-HEV IgG and IgM, HEV RNA) was studied in 609 sera samples of children with neurologic pathologies, 87 samples--from children with immune deficiencies, as well as 3122 samples from conditionally healthy children of 6 regions of Russia. The children were divided into 5 age groups. Anti-HEV IgG and IgM determination was carried out in EIA, HEV RNA--by RT-PCR. RESULTS: The frequency of detection of anamnestic anti-HEV IgG turned out to be significantly higher among immune-compromised. children compared with healthy children (5.7% against 1.4%, p < 0.05). Anti-HEV IgM, that testify to current or recent infection, were also detected significantly more frequently among children with immune-suppression (1.1-1.6%) compared with healthy children (0.25%, p < 0.05). HEV RNA was detected in 1 child with the absence of anti-HEV IgM and IgG. Nucleotide sequence analysis of HEV confirmed membership of this isolate in genotype 3, that is prevalent in non-endemic territories. CONCLUSION: The data obtained have demonstrated, that HEV-infection is prevalent among children in Russia and its course is, probably, asymptomatic in most cases. Immune suppression is a factor of increased risk of infection of children with HEV.
Subject(s)
Hepatitis Antibodies/blood , Hepatitis E virus/genetics , Hepatitis E/epidemiology , Hepatitis E/immunology , Immunocompromised Host , RNA, Viral/blood , Acute Disease , Adolescent , Child , Child, Preschool , Female , Hepatitis E/blood , Hepatitis E/virology , Hepatitis E virus/classification , Hepatitis E virus/isolation & purification , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant , Infant, Newborn , Male , Phylogeny , Prevalence , Russia/epidemiology , Sequence Analysis, RNA , Young AdultABSTRACT
AIM: To test clinical efficiency and immunocorrectives characteristics of polyoxidonium in patients with chronic bronchitis (CB) and chronic recurrent furunculosis. MATERIALS AND METHODS: 56 patients entered the trial; 13 with CB in remission, 22 with CB in exacerbation and 21 with chronic recurrent furunculosis. Clinical examinations and tests were made before polyoxidonium therapy and 2-3 days after it. Immunological tests consisted of determination of sub-population composition of peripheral blood lymphocytes, serum immunoglobulins and phagocytic activity of neutrophils. RESULTS: Polyoxidonium is an effective and safe immunocorrector. It has a strong influence on functional activity of blood phagocytic cells. CONCLUSION: Polyoxidonium treatment of CB and chronic recurrent furunculosis results in positive shifts in hematological and immunological indices. This allows to recommend it for treatment of acute and chronic infections.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Bronchitis/drug therapy , Furunculosis/drug therapy , Immunologic Deficiency Syndromes/drug therapy , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Antigens, CD/immunology , Bronchitis/complications , Bronchitis/immunology , Chronic Disease , Drug Therapy, Combination , Female , Follow-Up Studies , Furunculosis/complications , Furunculosis/immunology , Humans , Immunologic Deficiency Syndromes/etiology , Immunologic Deficiency Syndromes/immunology , Male , Middle Aged , Phagocytosis/drug effects , Phagocytosis/immunology , Recurrence , Russia , Safety , T-Lymphocytes/immunologyABSTRACT
AIM: Clinicoimmunological study of adult patients with prevailing defect of humoral immunity, development of diagnostic criteria and treatment of this disease. MATERIALS AND METHODS: Clinical, immunological and microbiological examinations were made in 68 patients with defects of antibody formation. RESULTS: Total variable immunodeficiency (TVID), selective deficiency of IgA, congenital agammaglobulinemia, hyper-IgM-syndrome were detected in 74, 13, 10 and 3% of patients, respectively. TVID was frequently associated with respiratory, chronic ENT and gastrointestinal diseases, low CD4+ and high CD8+ levels. The response was achieved with combined therapy: antibacterial treatment + immunocorrection + differentiated replacement with plasma or immunoglobulins. CONCLUSION: In choice of immunotherapy of TVID patients it is necessary to consider parameters of immunogram. Intravenous administration of immunoglobulin preparations provided the highest effect in good safety.
Subject(s)
Common Variable Immunodeficiency/therapy , Immunoglobulins, Intravenous/therapeutic use , Immunotherapy , Adolescent , Adult , Antibody Formation/immunology , B-Lymphocytes/immunology , Blood Component Transfusion , CD4-CD8 Ratio , Common Variable Immunodeficiency/blood , Common Variable Immunodeficiency/immunology , Follow-Up Studies , Humans , Immunoglobulin G/blood , Middle Aged , Plasma , Remission Induction , T-Lymphocytes/immunologyABSTRACT
AIM: Elucidation of likopid effect on clinical and immunological pictures in patients with chronic bronchitis (CB). MATERIALS AND METHODS: A trial of 52 CB patients in remission and exacerbation. 2 schemes of likopid treatment were used: 1 mg/day for 10 days (a course dose 10 mg); 10 mg/day for 6 days (a course dose 60 mg). Clinical and laboratory parameters, systemic immunity (measurement of lymphocyte subpopulations, levels of serum IgA, IgM and IgG, functional activity of peripheral blood phagocytes). RESULTS: The 10 mg and 60 mg courses of likopid produced prolongation of remission to 5-6 months in 66% of CB patients in exacerbation and in 80% of patients in remission, respectively. 10 mg of likopid in exacerbation and 60 mg in remission promoted normalization of functional activity of blood phagocytes. CONCLUSION: Likopid administration for CB in a 10 mg course dose in exacerbation and 60 mg course in remission prolongs CB remission to 5-6 months and promoted normalization of phagocytic functional activity.
